[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 327
6. Tlachacova D, Schmitt M, Novotny J Jr, Novotny J, Majali M, Liscak R: A comparison of the gamma knife model C and the automatic positioning system with Leksell model B. J Neurosurg; 2005 Jan;102 Suppl:25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data were obtained in 463 patients treated with the B model and 518 patients treated with the C model.
  • Data were analyzed in patients in whom the following diagnoses had been made: vestibular schwannoma, pituitary adenoma, meningioma, solitary metastasis, and other benign and malignant solitary tumors.
  • [MeSH-major] Adenoma / surgery. Automation / instrumentation. Brain Neoplasms / secondary. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Pituitary Neoplasms / surgery. Radiosurgery / instrumentation


7. Kalamarides M, Peyre M, Giovannini M: Meningioma mouse models. J Neurooncol; 2010 Sep;99(3):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery.
  • As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice.
  • Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported.
  • Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors.
  • These discoveries have led to the creation of a genetically engineered model utilizing conditional mutagenesis to specifically inactivate the mouse Nf2 gene in arachnoidal cells, resulting in the formation of intracranial meningothelial hyperplasia and meningiomas and thus reproducing the main mechanism of human meningeal tumorigenesis.
  • [MeSH-major] Disease Models, Animal. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):197-201 [11266526.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):545-50 [2477514.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):750-9; discussion 759-60 [17415213.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Proc Soc Exp Biol Med. 1977 May;155(1):85-8 [193127.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):943-7 [14612971.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] J Neurosurg. 1995 May;82(5):864-73 [7714613.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):130-5; discussion 135-6 [9442514.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Surg Neurol. 2001 May;55(5):275-83 [11516467.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 2001 Aug;15(4):328-34 [11599449.001]
  • [Cites] Toxicol Pathol. 2007 Oct;35(6):780-7 [17943659.001]
  • [Cites] J Neurosci. 1997 Apr 1;17(7):2376-82 [9065498.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):584-7 [3559725.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):326-32 [14672264.001]
  • [Cites] Clin Neuropathol. 1994 Mar-Apr;13(2):82-7 [8205731.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] Exp Toxicol Pathol. 2008 Aug;60(4-5):247-51 [18524558.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):720-4 [7501018.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Brain Tumor Pathol. 1997;14 (2):139-43 [15726793.001]
  • [Cites] Cell. 1987 Nov 6;51(3):503-12 [2822260.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6090-3 [7954452.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):295-307; discussion 307 [18261772.001]
  • [Cites] Cell Prolif. 2005 Feb;38(1):3-12 [15679862.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):202-14 [10669008.001]
  • [Cites] Brain Pathol. 2008 Apr;18(2):172-9 [18093250.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • (PMID = 20734219.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


8. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology; 2007 Apr;27(2):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas represent the second most common central nervous system neoplasms in adults and account for 26% of all primary brain tumors.
  • Although most are benign, between 5% and 15% of meningiomas are atypical (grade II) whereas 1-2% are anaplastic meningiomas (grade III).
  • Although histological grade is the most relevant prognostic factor, there are some unusual cases in which establishing a diagnosis of high-grade meningioma following 2000 World Health Organization (WHO) histological criteria is extremely difficult.
  • Therefore, the aim of the present study was to evaluate the predictive value of Ki-67 labeling index and its contribution to current WHO classification in predicting tumor recurrence and overall survival in patients with high-grade meningiomas.
  • In the univariate analysis, Ki-67 labeling index and postoperative Karnofsky performance status were identified as significant prognostic factors of tumor recurrence and overall survival.
  • The multivariate analysis demonstrated that Ki-67 labeling index is the only independent predictor of both tumor recurrence and overall survival.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neuropathology. 2008 Feb;28(1):106-7 [18181839.001]
  • (PMID = 17494511.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


9. Ahmadi SA, Samadi N: Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas. Ann Saudi Med; 2006 Jan-Feb;26(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparing nonrecurrent, recurrent, atypical and malignant meningiomas we studied the value of the routine applicability of the AgNOR count in the prognostication of this tumor.
  • Eighty-one cases were selected and arranged in six groups according to clinical data and grading: 14 benign non-recurrent meningiomas; 14 primary benign recurrent meningiomas and their subsequent benign recurrences; 14 atypical; 11 malignant and 14 spinal meningiomas.
  • RESULTS: There was a proportionate increase of AgNOR dots with increasing tumor grade.
  • There was a significant difference between benign non-recurrenttumors versus benign recurrent (P<0.0001) and atypical or malignant (P<0.0001) tumors.
  • A difference was also noted between the recurring tumors versus malignant ones (P = 0.002) but no significant difference was seen between recurrent and atypical; atypical and malignant; intracranial and intraspinal; and primary of recurring meningiomas with their subsequent recurrences.
  • A mean AgNOR count of <2.3 could separate benign tumors from atypical or malignant meningiomas with 93% specificity; and 93% of tumors with benign histology had no recurrence potential if their mean AgNOR count was less than 1.8.
  • CONCLUSION: This study indicates that in meningioma, the AgNOR count has a good correlation with tumor grading and recurrence, which may aid pathologists and clinicians in predicting tumor behavior.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Nucleolus Organizer Region / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521873.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


10. Khadilkar UN, Agarwal N, Deeshma, Bhat V: Primary meningeal melanocytoma. Kathmandu Univ Med J (KUMJ); 2008 Apr-Jun;6(2):245-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary meningeal melanocytoma.
  • Meningeal melanocytoma is an uncommon benign pigmented primary lesion that has to be distinguished as a pathological entity separate from other benign melanin containing tumours as well as its overtly malignant counterpart, melanoma.
  • [MeSH-major] Melanoma / pathology. Meningeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769099.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


11. Roser F, Nakamura M, Ritz R, Bellinzona M, Dietz K, Samii M, Tatagiba MS: Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Cancer; 2005 Aug 1;104(3):598-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
  • Of these, 588 tumor specimens from 554 patients who underwent surgery between 1990 and 2000 were evaluated immunohistochemically.
  • Correlations with histologic subtype, disease recurrence-free survival, resection grade, location, size, vascularity, and tumor calcification were calculated as well.
  • CONCLUSIONS: Proliferation rates and PR status in benign intracranial meningiomas did not appear to be age dependent.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Proliferation. Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Antibodies, Antinuclear. Antibodies, Monoclonal. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15952201.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / Receptors, Progesterone
  •  go-up   go-down


12. Böthig R, Rogosch KU, Mach P, Mahn B, Burgdörfer H: [Testicular metastases as primary manifestation of malignant melanoma at known melanocytoma]. Aktuelle Urol; 2006 Mar;37(2):138-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Secondary tumors of the testes are rare.
  • In about 15 % of the cases they are metastases of a malignant melanoma, there are about 30 reports of such cases in the literature.
  • Most of them describe findings at post-mortem, in only 4 of the previously described cases testicular metastases were the first manifestation of a melanoma.
  • The transformation of a benign, meningeal melanocytoma into a malignant melanoma has only been described once world-wide.
  • The problems in the diagnosis and therapy of this extremely rare tumor are discussed on the basis of a further patient with metastases of the testes as primary manifestation of a malignant melanoma.
  • The case history disclosed operations 10 and 3.5 year earlier for an apparently benign melanocytoma at the level of the 11th and 12th thoracic vertebrae, a local recurrence with paraparesis was known at the time of admission.
  • Sonography revealed an inhomogeneous tumor effecting the entire left testicle.
  • The correct diagnosis was made histologically.
  • CONCLUSION: In the case of a primary manifestation a correct preoperative diagnosis is unusual.
  • Radical orchiectomy is the treatment of choice for a suspected primary testicular tumor.
  • In elderly patients with unclear testicular tumors metastases from an (occult) tumor disease must be taken into consideration.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanocytes. Melanoma / secondary. Meningeal Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Testicular Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Orchiectomy. Testis / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625471.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Zhi L, Bing L, Yang L, Bo-ning L, Quan H: Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature. Pathol Res Pract; 2009;205(8):582-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas usually present as benign tumors corresponding to WHO grade I.
  • The tumor exhibits a marked peritumoral cyst, with contrast enhancement on magnetic resonance imaging (MRI) in accordance with type 2 of Zee's classification of cystic meningioma.
  • Histologically, the tumor displays a classical perivascular pseudopapillary pattern with focal necrosis and subarachnoid space dissemination.
  • Tumor cells are diffusely positive for epithelial membrane antigen (EMA) and vimentin, but lack immunoreactivity for cytokeratin (CK) and glial fibrillary acidic protein (GFAP).
  • MIB-1 labeling is high, accounting for 5% of tumor focally.
  • A diagnosis of primary intraventricular cystic papillary meningioma with subarachnoid space dissemination (WHO grade III) was made.
  • In addition, the biological behavior and the clinical outcome of this tumor are also discussed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Magnetic Resonance Imaging. Mucin-1 / metabolism. Neoplasm Staging. Treatment Outcome. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307065.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


1
Advertisement
4. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


15. Sajja R, Barnett GH, Lee SY, Harnisch G, Stevens GH, Lee J, Suh JH: Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results. Technol Cancer Res Treat; 2005 Dec;4(6):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate tumor control, complications, and outcome from intensity-modulated radiation therapy (IMRT) for intracranial meningiomas.
  • Thirty-five patients with 37 lesions (35 benign and two atypical histology) were identified with a minimum of six months of radiologic follow-up for this retrospective review.
  • Twenty meningiomas (54%) were previously treated with surgery/radiosurgery prior to IMRT, and 17 meningiomas (46%) were treated with IMRT primarily after diagnosis was established by MRI/CT.
  • The median tumor dose was 50.4 Gy prescribed to the 87% isodose line providing a median target coverage of 95%.
  • A greater number of patients with longer follow-up after treatment may be needed to determine treatment variables predicting for long-term tumor control.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292888.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kärjä V, Sandell PJ, Kauppinen T, Alafuzoff I: Does protein expression predict recurrence of benign World Health Organization grade I meningioma? Hum Pathol; 2010 Feb;41(2):199-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
  • Thus, the expression of proteins that have been reported to be associated with prognosis of meningiomas was assessed in a sample of 59 World Health Organization grade I tumors obtained after Simpson grade I to III surgical resection (complete excision) and that were followed for 6 to 16 years.
  • Our results indicate that the Simpson grade significantly alters the outcome of a World Health Organization I grade meningioma and a longer follow-up period significantly increases the risk of recurrence.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Chi-Square Distribution. Female. Hepatocyte Growth Factor / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Regression Analysis. Tissue Array Analysis. World Health Organization

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19801161.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HGF protein, human; 0 / Ki-67 Antigen; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


17. Marcus HJ, Price SJ, Wilby M, Santarius T, Kirollos RW: Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg; 2008 Aug;22(4):520-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study, therefore, was to appraise the evidence for adjuvant radiotherapy in benign and atypical intracranial meningiomas, and to compare and contrast it with the current opinion and practice of neurosurgeons in the United Kingdom and the Republic of Ireland.
  • We performed a systematic review of the evidence for adjuvant radiotherapy in benign and atypical intracranial meningiomas, surveyed current opinion amongst neurosurgeons involved in such cases and ascertained local practice using data from the regional cancer registry.
  • [MeSH-major] Evidence-Based Medicine. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy
  • [MeSH-minor] Female. Great Britain. Humans. Ireland. Male. Neoplasm Staging. Practice Guidelines as Topic. Radiotherapy, Adjuvant

  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803079.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 67
  •  go-up   go-down


18. Schaller B: Spinal meningioma: relationship between histological subtypes and surgical outcome? J Neurooncol; 2005 Nov;75(2):157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraspinal meningiomas are slow growing benign tumors that produce indolent neurological deficits, which are often reversible following operation.
  • Mean age of the 30 women (91%) and the 3 men (9%) was 63+/-20 years (range 22-88).
  • Tumor position was laterally in 19 (58%), posteriorly in 8 (24%) and anteriorly in 6 (18%) patients.
  • Following tumor resection, neurological deficits resolved in 26 of 33 patients (79%) and worsened in 7 of 33 patients (21%) all of the latter had meningiomas of the psammomatous type.
  • Posterior or lateral tumor position in the spinal canal, location below C4, age less than 60 years, and duration of preoperative symptoms seem to be correlated with a good outcome.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / pathology. Meningioma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Angiography. Chi-Square Distribution. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Myelography. Neoplasm Recurrence, Local. Neurologic Examination. Prognosis. Regression Analysis. Retrospective Studies. Sex Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Tumor Burden. X-Rays

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurosurg. 1982 Dec;57(6):804-12 [7143063.001]
  • [Cites] J Neurosurg. 1986 Feb;64(2):253-6 [3003263.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):353-60 [422988.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Acta Neurol Scand. 1988 Jan;77(1):27-30 [3354308.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):465-71 [10392201.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):629-31 [2234369.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Feb;112(2):228-34 [7838543.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):646-8 [2926506.001]
  • [Cites] Ann Surg. 1940 Apr;111(4):513-30 [17857556.001]
  • [Cites] J Neurosurg. 1987 May;66(5):695-700 [3572496.001]
  • [Cites] Neurosurgery. 1989 Aug;25(2):153-60 [2671779.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • (PMID = 16132511.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Davidson L, Fishback D, Russin JJ, Weiss MH, Yu C, Pagnini PG, Zelman V, Apuzzo ML, Giannotta SL: Postoperative Gamma Knife surgery for benign meningiomas of the cranial base. Neurosurg Focus; 2007;23(4):E6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative Gamma Knife surgery for benign meningiomas of the cranial base.
  • The authors analyzed the mid- and long-term results obtained in patients treated with postresection Gamma Knife surgery (GKS) for residual or recurrent benign meningiomas of the cranial base.
  • METHODS: Thirty-six patients with residual or recurrent benign meningiomas of the skull base following one or more surgical procedures underwent GKS.
  • There were 31 women and five men, ranging in age from 22 to 73 years.
  • The median tumor volume was 4.1 ml (range 0.8-20 ml) and the median radiation dose to the tumor margin was 16 Gy (range 15-16 Gy).
  • Based on imaging documentation, a partial response was seen in five patients (13.9%), the disease remained stable in 30 patients (83.3%), and in one patient (2.8%) there was an increase in tumor size.
  • CONCLUSIONS: Gamma Knife surgery was shown to be an excellent adjunct to resection because of its durable rate of tumor control and low toxicity.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961043.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


21. Grujicić M, Vucković N, Vuleković P: [Morphological characteristics of meningiomas]. Med Pregl; 2010 Mar-Apr;63(3-4):237-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Meningiomas are common intracranial neoplasms which originate from the soft meninges, precisely from meningeal arachnoidal cells.
  • It included 490 consecutive patients of both sexes with diagnosed intracranial tumors and undergoing surgical treatment at the Neurosurgery Clinic of the Clinical Center of Vojvodina.
  • Out of 490 patients with diagnosed intracranial tumors, 137 (27.96%) were diagnosed to have meningiomas.
  • In regard to other histological types of intracranial tumors, meningiomas were more frequent in females (36.3%).
  • The commonest histological types of meningiomas were benign meningiomas (93.4%).
  • Malignant histological types of meningiomas were more common in males (83.3%), whereas benign histological types were more common in females (64.1%).
  • The tumor is located in the left frontal region.
  • On histology it is benign, transitional type of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053467.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


22. Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM: Tissue transgluaminase 2 expression in meningiomas. J Neurooncol; 2008 Nov;90(2):125-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are common intracranial tumors that occur in extra-axial locations, most often over the cerebral convexities or along the skull-base.
  • Although often histologically benign these tumors frequently present challenging clinical problems.
  • Primary clinical management of patients with symptomatic tumors is surgical resection.
  • Radiation treatment may arrest growth or delay recurrence of these tumors, however, meningioma cells are generally resistant to apoptosis after treatment with radiation.
  • Tumor cells are known to alter their expression of proteins that interact in the ECM to provide signals important in tumor progression.
  • One such protein, fibronectin, is expressed in elevated levels in the ECM in a number of tumors including meningiomas.
  • KCC009 treatment promoted apoptosis and enhanced radiation sensitivity both in cultured IOMM-Lee meningioma cells and in meningioma tumor explants.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. Putrescine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):825-38 [10684262.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2563-73 [17099729.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2989-3000 [11686302.001]
  • [Cites] Breast Cancer Res Treat. 2002 Feb;71(3):237-47 [12002342.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):302-6 [12073047.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Sep;2(3):257-77 [12188911.001]
  • [Cites] Trends Biochem Sci. 2002 Oct;27(10):534-9 [12368090.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1652-4; author reply 1654 [12419794.001]
  • [Cites] Biochem J. 2002 Dec 1;368(Pt 2):377-96 [12366374.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):140-56 [12563291.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Apr;28(4):428-35 [12654631.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42604-14 [12732629.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50402-11 [14523021.001]
  • [Cites] Int J Radiat Biol. 2003 Sep;79(9):709-20 [14703944.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):95-102 [15102436.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Acta Neuropathol. 1985;66(3):245-52 [3893018.001]
  • [Cites] J Neuropathol Exp Neurol. 1986 May;45(3):285-303 [3083053.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Science. 1994 Jun 10;264(5165):1593-6 [7911253.001]
  • [Cites] J Cell Biochem. 1994 Sep;56(1):37-47 [7806590.001]
  • [Cites] Science. 1995 Apr 14;268(5208):233-9 [7716514.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2783-93 [9184223.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4406-18 [9234699.001]
  • [Cites] Curr Opin Cell Biol. 1997 Oct;9(5):701-6 [9330874.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1658-67 [10029595.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):8068-76 [15585642.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Chem Biol. 2005 Apr;12(4):469-75 [15850984.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):32-7 [15850899.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 12;333(4):1269-75 [15979576.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1293-302 [16170020.001]
  • [Cites] J Neurochem. 2000 Nov;75(5):1951-61 [11032884.001]
  • (PMID = 18587533.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK063158; United States / NIDDK NIH HHS / DK / R01 DK63158
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Fibronectins; 0 / Isoxazoles; 0 / KCC 009; 10028-17-8 / Tritium; EC 2.3.2.- / transglutaminase 2; EC 2.3.2.13 / Transglutaminases; EC 3.6.1.- / GTP-Binding Proteins; V10TVZ52E4 / Putrescine
  • [Other-IDs] NLM/ NIHMS488704; NLM/ PMC3732188
  •  go-up   go-down


23. Linskey ME, Davis SA, Ratanatharathorn V: Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single-surgeon 4-year integrated experience with both modalities. J Neurosurg; 2005 Jan;102 Suppl:59-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean tumor coverage was 94.7%, and the mean conformity index was 1.76.
  • Significant differences between the two treatment groups (GKS compared with microsurgery) included age (mean 60 compared with 50.7 years), volume (mean 7.85 cm3 compared with 44.4 cm3), treatment history (55.3% compared with 14.3%), and tumor location (cavernous sinus/petroclival, 14 compared with three).
  • In patients with benign meningiomas GKS tumor control was 96.8% with one recurrence at the margin.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Microsurgery / instrumentation. Radiosurgery / instrumentation. Skull Base / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Radiation Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662783.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Wickremesekera A, Hovens CM, Kaye AH: Expression of ErbB-1 and ErbB-2 in meningioma. J Clin Neurosci; 2010 Sep;17(9):1155-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are benign intracranial tumours treated by neurosurgical resection.
  • Residual or recurrent tumour may be treated with radiotherapy.
  • These preliminary results implicate a potential role for ErbB-2 in the benign tumourigenesis of meningioma consistent with the theoretical hierarchical interactions of homodimers of ErbB-2 that may be associated with low signal transduction.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20547458.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


25. Ichinose T, Goto T, Ishibashi K, Takami T, Ohata K: The role of radical microsurgical resection in multimodal treatment for skull base meningioma. J Neurosurg; 2010 Nov;113(5):1072-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Because resection followed by timely stereotactic radiosurgery (SRS) is becoming a standard strategy for skull base meningiomas, the role of initial surgical tumor reduction in this combined treatment should be clarified.
  • METHODS: This study examined 161 patients with benign skull base meningiomas surgically treated at Osaka City University between January 1985 and December 2005.
  • Patients were categorized into 3 groups based on the operative period and into 4 groups based on tumor location.
  • In the early period (1985-1994), in the absence of SRS, total excision of the tumor was intentionally performed for surgical cure of the disease.
  • In the mid and late periods (1995-2000 and 2001-2005), small parts of the tumor invading critical neurovascular structures were left untouched to obtain good functional results.
  • Residual tumors with high proliferation potential (Ki 67 index > 4%) or with progressive tendencies were treated with SRS.
  • The extent of initial tumor resection, recurrence rate, Karnofsky Performance Scale score, and complication rate were investigated in each group.
  • RESULTS: The mean tumor equivalent diameter of residual tumors was 3.67 mm in the no-recurrence group and 11.7 mm in the recurrence group.
  • The mean tumor resection rate (TRR) was 98.5% in the no-recurrence group and 90.1% in the recurrence group.
  • A significant relationship was seen between postoperative tumor size, TRR, and recurrence rate (p < 0.001), but the recurrence rate showed no significant relationship with any other factors such as operative period (p = 0.48), tumor location (p = 0.76), or preoperative tumor size (p = 0.067).
  • Throughout all follow-up periods, 158 tumors were satisfactorily controlled by maximal possible excision alone or in combination with adequate SRS.
  • A TRR greater than 97% in volume can be achieved with satisfactory functional preservation and will lead to excellent tumor control in combined treatment of skull base meningioma.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiosurgery. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Nov;113(5):1123
  • (PMID = 20225926.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. McGuire TP, Palme CE, Perez-Ordonez B, Gilbert RW, Sándor GK: Primary intraosseous meningioma of the calvaria: analysis of the literature and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Oct;104(4):e34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common of the benign intracranial neoplasms.
  • We report the case of a rare primary intraosseous meningioma presenting as a localized, symptom-free supraorbital bony expansion in an 81-year-old female patient and tabulate the previously reported cases of primary intraosseous meningiomas of the craniomaxillofacial region for analysis.
  • [MeSH-major] Frontal Bone / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656124.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


27. Barnholtz-Sloan JS, Kruchko C: Meningiomas: causes and risk factors. Neurosurg Focus; 2007;23(4):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are among the most common primary intracranial tumors.
  • Although the vast majority of these tumors are considered histologically benign, the incidence of complications can be high.
  • [MeSH-major] Meningeal Neoplasms / etiology. Meningioma / etiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961039.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Grant] United States / PHS HHS / / 2004-01218
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones
  • [Number-of-references] 113
  •  go-up   go-down


28. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


29. Perrini P, Caniglia M, Pieroni M, Castagna M, Parenti GF: Malignant transformation of intramedullary melanocytoma: case report. Neurosurgery; 2010 Sep;67(3):E867-9; discussion E869
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningeal melanocytomas are low-grade primary melanocytic tumors with benign histological features and a favorable clinical prognosis.
  • Transition from meningeal melanocytoma to primary melanoma of the central nervous system is exceptionally rare, with only 5 cases having been previously reported.
  • Two years later, the tumor recurred locally, and the patient underwent additional surgery to remove the intramedullary mass.
  • The histological findings of the tumor were consistent with an intramedullary malignant melanoma.
  • CONCLUSION: The malignant transformation of melanocytic tumors of the central nervous system may occur years after surgical treatment, and its incidence remains unknown.
  • Emphasis should be placed on the importance of careful and continued follow-up monitoring of the tumor.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Nevus, Pigmented / pathology. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657325.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Maes L, Kalala JP, Cornelissen M, De Ridder L: PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo; 2006 Mar-Apr;20(2):271-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCNA, Ki-67 and hTERT in residual benign meningiomas.
  • BACKGROUND: Relapse in individual patients after incomplete/residual removal of meningiomas cannot be predicted by histology alone as re-growth occurs even in histologically benign meningiomas.
  • The labelling index (LI) expressed the percentage of tumour cell nuclei immunoreactive for PCNA, Ki-67 or hTERT in 1,000 tumour cells counted per section.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual / metabolism. Neoplasm, Residual / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634530.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


31. Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T: Early malignant transformation of a petroclival meningothelial meningioma. Neurosurg Rev; 2009 Oct;32(4):495-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early malignant transformation of a petroclival meningothelial meningioma.
  • The tumor was subtotally removed and was diagnosed to be a meningothelial meningioma.
  • Seven months after surgery, a recurrence of the tumor was confirmed.
  • The diagnosis of this recurrent tumor was an atypical meningioma.
  • The MIB-1 index and the percent of p53 protein-positive cells in the primary tumor were 4.6% and 35.4%, respectively, whereas those of the recurrent tumor were 34.7% and 33.1%, respectively.
  • A chromosomal DNA copy number loss was observed on 1p, 6q, 10, 14q, and -22q detected in both the primary and the recurrent tumors.
  • These results suggest that the present case had a potentially malignant tumor in the early stage, although it had the histological features of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Cerebral Angiography. DNA / genetics. Female. Gait Disorders, Neurologic. Gene Dosage. Hearing Disorders / etiology. Humans. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Meningeal Arteries / surgery. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2003 Aug;7(4):214-22 [12913843.001]
  • [Cites] Cell. 1998 Oct 2;95(1):5-8 [9778240.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):29-33 [9426052.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):148-51 [14734228.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1313-8 [1886708.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):857-61 [4056899.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2386-92 [8485725.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):67-75 [10736068.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):354-7 [8314321.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Neuropathol Appl Neurobiol. 1995 Apr;21(2):136-42 [7609844.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):398-404 [17695396.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):62-7 [11333301.001]
  • [Cites] J Med Genet. 2006 Mar;43(3):285-7 [15980114.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • (PMID = 19533187.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


32. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien); 2010 Oct;152(10):1711-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperative 440 nm fluorescence was applied periodically during and at the end of resection in order to detect tumor-infiltrated sites.
  • The fluorescence of the tumor was evaluated intraoperatively by the surgeon and confirmed by subsequent video analysis.
  • RESULTS: A total of 32 (97%) patients presented with benign meningiomas (WHO I-II).
  • 5-ALA-induced fluorescence of the tumor was confirmed in a total of 31 (94%) patients.
  • [MeSH-major] Aminolevulinic Acid. Fluorescence. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Monitoring, Intraoperative / methods. Photosensitizing Agents
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / prevention & control. Preoperative Care / methods. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535506.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


33. McGregor JM, Sarkar A: Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas. Otolaryngol Clin North Am; 2009 Aug;42(4):677-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most common nonglial brain tumors.
  • They tend to be slow growing and benign and can reach substantial sizes before becoming symptomatic.
  • Location of a meningioma within the cranial vault may make complete surgical resection unlikely; tumors arising from the dura of the skull base are particularly challenging.
  • They may be used as adjuncts to surgery or as alternative modalities in the treatment of these complex tumors.
  • [MeSH-major] Meningioma / radiotherapy. Meningioma / surgery. Neoplasm Recurrence, Local / pathology. Radiosurgery / methods. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Cranial Irradiation / adverse effects. Cranial Irradiation / methods. Dose-Response Relationship, Radiation. Female. Humans. Immunohistochemistry. Male. Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Radiation Injuries / prevention & control. Radiotherapy Dosage. Risk Assessment. Stereotaxic Techniques. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751872.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


34. O'Brien DF, Crooks D, Mallucci C, Javadpour M, Williams D, du Plessis D, Broome J, Foy P, Pizer B: Meningeal melanocytoma. Childs Nerv Syst; 2006 Jun;22(6):556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal melanocytoma.
  • BACKGROUND: Meningeal melanocytoma was first described over 30 years ago as a benign tumour derived from melanocytes.
  • Although classified as a benign tumour, this tumour shows a marked tendency towards reduced survival following subtotal resection and transformation over time in a limited number to malignant melanoma.
  • Its classification as a benign tumour should be revised, given the published 5-year survival data.
  • ILLUSTRATIVE CASE: We report a fatal case of meningeal melanocytoma in the cerebello-pontine angle in a 10-year-old child.
  • [MeSH-major] Melanoma / pathology. Melanoma / therapy. Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2002 Nov;9(6):637-9 [12604273.001]
  • [Cites] Surg Neurol. 2003 Mar;59(3):200-10 [12681556.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurosurg. 2004 Sep;101(3):528-31 [15352613.001]
  • [Cites] Arq Neuropsiquiatr. 1981 Mar;39(1):42-9 [7259589.001]
  • [Cites] Neurol Neurochir Pol. 1987 Jan-Feb;21(1):60-5 [3614525.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(6):621-8 [9755333.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3 Suppl Spine):287-90 [15029918.001]
  • [Cites] Ugeskr Laeger. 2000 Apr 3;162(14):2052-3 [10815523.001]
  • [Cites] Pediatr Neurosurg. 2000 May;32(5):240-7 [10965270.001]
  • [Cites] Arq Neuropsiquiatr. 1979 Jun;37(2):180-4 [496706.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):619-23 [11883852.001]
  • [Cites] Neurochirurgie. 2001 May;47(2-3 Pt 1):133-6 [11404684.001]
  • [Cites] Brain Tumor Pathol. 2003;20(1):21-5 [14604228.001]
  • [Cites] Arch Neurobiol (Madr). 1989 Mar-Apr;52(2):93-9 [2667490.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):50-7 [3783260.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):259-63 [14558602.001]
  • [Cites] J Neurosurg. 1978 Aug;49(2):301-2 [671085.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2004 Jan 17;84(2):134-7 [14990130.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):705-9 [1545267.001]
  • [Cites] Neuroradiology. 1997 Nov;39(11):811-4 [9406208.001]
  • [Cites] Neurology. 1977 Jul;27(7):650-5 [559971.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):542-6 [7605172.001]
  • [Cites] Cancer. 1972 Nov;30(5):1286-94 [4343293.001]
  • [Cites] J Neurosurg. 2001 Oct;95(2 Suppl):225-31 [11599841.001]
  • [Cites] Br J Neurosurg. 2003 Aug;17(4):347-51 [14579901.001]
  • (PMID = 16491422.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Nagar VA, Ye JR, Ng WH, Chan YH, Hui F, Lee CK, Lim CC: Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol; 2008 Jun;29(6):1147-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.
  • BACKGROUND AND PURPOSE: Atypical and malignant meningiomas are uncommon tumors with aggressive behavior and higher mortality, morbidity, and recurrence compared with benign tumors.
  • We investigated the utility of diffusion-weighted (DW) MR imaging to differentiate atypical/malignant from benign meningiomas and to detect histologic dedifferentiation to higher tumor grade.
  • MATERIALS AND METHODS: We retrospectively compared conventional and DW MR images (b-value 1000 s/mm(2)) acquired on a 1.5T clinical scanner between 25 atypical/malignant and 23 benign meningiomas.
  • RESULTS: Irregular tumor margins, peritumoral edema, and adjacent bone destruction occurred significantly more often in atypical/malignant than in benign meningiomas.
  • The mean ADC of atypical/malignant meningiomas (0.66 +/- 0.13 x 10(-3) mm(2)/s) was significantly lower compared with benign meningiomas (0.88 +/- 0.08 x 10(-3) mm(2)/s; P < .0001).
  • Mean NADC ratio in the atypical/malignant group (0.91 +/- 0.18) was also significantly lower than the benign group (1.28 +/- 0.11; P < .0001), without overlap between groups.
  • Two patients had isointense benign tumors on initial DW MR imaging, and these became hyperintense with the decrease in ADC and NADC below these thresholds when they progressed to atypical and malignant meningiomas on recurrence.
  • CONCLUSIONS: ADC and NADC ratios in atypical/malignant meningiomas are significantly lower than in benign tumors.
  • Decrease in ADC and NADC on follow-up imaging may suggest dedifferentiation to higher tumor grade.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2009 Feb;30(2):E21 [19193747.001]
  • (PMID = 18356472.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Aghi MK, Eskandar EN, Carter BS, Curry WT Jr, Barker FG 2nd: Increased prevalence of obesity and obesity-related postoperative complications in male patients with meningiomas. Neurosurgery; 2007 Oct;61(4):754-60; discussion 760-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively reviewed male patients who underwent craniotomy for benign meningiomas at our institution between 2001 and 2005 (n = 32) and used male patients undergoing craniotomy for aneurysms (n = 32) or glioblastomas (n = 32) from 2001 to 2005 as control subjects.
  • The obesity rate in men with meningiomas (47%) exceeded that in men with aneurysms (19%) or gliomas (3%) (P = 0.2).
  • The median age-normalized BMI percentile was greater in men with meningiomas (67 th percentile) than in men with aneurysms (49th percentile) or gliomas (52 nd percentile) (P = 0.02).
  • Deep vein thrombosis/pulmonary embolus was more common in men with meningiomas (19%) than in men with aneurysms (0%) or gliomas (3%) (P = 0.002).
  • Wound infections were more common in men with meningiomas (6%) than in men with aneurysms (3%) or gliomas (0%) (P = 0.2).
  • CONCLUSION: We found that many men with meningiomas are obese, suggesting a hormonal influence on meningiomas in men as well as women.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Obesity / epidemiology. Postoperative Complications / epidemiology

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986936.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ginat DT, Mangla R, Yeaney G, Wang HZ: Correlation of diffusion and perfusion MRI with Ki-67 in high-grade meningiomas. AJR Am J Roentgenol; 2010 Dec;195(6):1391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Atypical and anaplastic meningiomas have a greater likelihood of recurrence than benign meningiomas.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blood Volume. Cerebrovascular Circulation. Diffusion Magnetic Resonance Imaging. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Linear Models. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21098200.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


38. Stienen MN, Lücke S, Fournier JY, Hildebrandt G, Gautschi OP: [The intracranial meningioma - therapeutic possibilities and limitations]. Praxis (Bern 1994); 2010 Dec 1;99(24):1479-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 90 percent of these mostly slow growing meningiomas are benign.
  • [MeSH-major] Meningeal Neoplasms / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21125533.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Damek DM: Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. Emerg Med Clin North Am; 2009 May;27(2):209-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer-related neurologic syndromes are rarely pathognomonic and must be differentiated from other benign or serious conditions.
  • [MeSH-major] Brain Diseases / therapy. Emergency Service, Hospital. Neoplasms / complications
  • [MeSH-minor] Brain Edema / etiology. Brain Edema / therapy. Delirium / etiology. Delirium / therapy. Humans. Meningeal Neoplasms / secondary. Paraneoplastic Syndromes, Nervous System / etiology. Paraneoplastic Syndromes, Nervous System / therapy. Seizures / etiology. Seizures / therapy. Stroke / etiology. Stroke / therapy

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Hematol Oncol Clin North Am. 2010 Jun;24(3):515-35 [20488351.001]
  • (PMID = 19447307.001).
  • [ISSN] 1558-0539
  • [Journal-full-title] Emergency medicine clinics of North America
  • [ISO-abbreviation] Emerg. Med. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


40. Terzi A, Saglam EA, Barak A, Soylemezoglu F: The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract; 2008;204(5):305-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas) using tissue microarray.
  • The tumors were graded according to the World Health Organization classification.
  • In contrast, multivariate analysis revealed that only tumor grade is an independent factor for predicting meningioma recurrence.
  • We conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas, especially in histological borderline cases.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Immunohistochemistry. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Logistic Models. Male. Middle Aged. Neoplasm Staging. Neurofibromatosis 2 / immunology. Neurofibromatosis 2 / metabolism. PTEN Phosphohydrolase / analysis. Recurrence. Risk Assessment. Time Factors. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374497.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


41. Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, García-Guereta L, López-Gutiérrez JC, Olivares P, Tovar J: Association of cutaneous red-to-purple hemangiomas with leptomeningeal hemangiomas. a clinical study of two patients. Neuropediatrics; 2010 Feb;41(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous hemangioma is a benign vascular tumor of infancy with an initial proliferating period that appears between 1 to 2 weeks of life, extends during 18 months to 2 years of life, and then slowly regresses during several years until it disappears completely.
  • [MeSH-major] Hemangioma. Meningeal Neoplasms. Skin Diseases, Vascular. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571984.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


42. Schultze J, Eilf K: [Perspectives of radiation therapy in benign diseases]. Strahlenther Onkol; 2006 May;182(5):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perspectives of radiation therapy in benign diseases].
  • [Transliterated title] Perspektiven der Strahlentherapie gutartiger Erkrankungen.
  • Regularly, more women than men were treated, median age annually was 57, 54, and 55 years, respectively (Table 1).
  • CONCLUSION: Due to administrative restrictions for treatment in hospitals, budget restrictions in private practices and lasting, insufficient revenues for radiotherapy in nonmalignant diseases, radiation therapy for the entire group of benign diseases is endangered.
  • [MeSH-major] Arthritis / radiotherapy. Graves Ophthalmopathy / radiotherapy. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Ossification, Heterotopic / radiotherapy. Radiotherapy / trends. Tendinopathy / radiotherapy

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Tendinitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673058.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT: Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg; 2005 Sep;103(3):508-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Meningiomas are the second most common symptomatic primary central nervous system tumor in adults.
  • One hundred eleven (87%) of 128 benign meningiomas and six (86%) of seven atypical meningiomas displayed a high COX-2 immunoreactivity (Grade 4 staining).
  • [MeSH-major] Cyclooxygenase Inhibitors / pharmacology. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Prostaglandin-Endoperoxide Synthases / biosynthesis. Pyrazoles / pharmacology. Sulfonamides / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Blotting, Western. Celecoxib. Cell Proliferation. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Male. Membrane Proteins. Middle Aged. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235684.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


44. Sturges BK, Dickinson PJ, Bollen AW, Koblik PD, Kass PH, Kortz GD, Vernau KM, Knipe MF, Lecouteur RA, Higgins RJ: Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs. J Vet Intern Med; 2008 May-Jun;22(3):586-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intracranial meningiomas are the most common primary brain tumors in dogs.
  • Classification of meningiomas by tumor grade and subtype has not been reported, and the value of magnetic resonance imaging (MRI) characteristics for predicting tumor subtype and grade has not been investigated.
  • HYPOTHESIS: Canine intracranial meningiomas are a heterogenous group of tumors with differing histological subtypes and grades.
  • ANIMALS: One hundred and twelve dogs with a histological diagnosis of intracranial meningioma.
  • The incidence of specific tumor grades was 56% benign (Grade I), 43% atypical (Grade II), and 1% malignant (Grade III).
  • No statistically significant (P < .05) associations were found among tumor subtype or grade and any of the MRI features studied.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Meningiomas in dogs differ from their counterparts in humans mainly in their higher incidence of atypical (Grade II) tumors observed.
  • MRI characteristics do not allow for prediction of meningioma subtype or grade, emphasizing the necessity of histopathology for antemortem diagnosis.
  • The higher incidence of atypical tumors in dogs may contribute to the poorer therapeutic response in dogs with meningiomas as compared with the response in humans with meningiomas.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466258.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ruiz J, Martínez A, Hernández S, Zimman H, Ferrer M, Fernández C, Sáez M, López-Asenjo JA, Sanz-Ortega J: Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Histol Histopathol; 2010 03;25(3):341-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
  • The WHO grading scheme distinguishes benign (grade I), atypical (grade II) and anaplastic (grade III) meningiomas.
  • Both atypical and anaplastic meningiomas exhibited an overall increased rate of recurrence, but between 15-20% benign meningiomas will also exhibit an unfavourable clinical course with recurrence before 10 years despite aggressive surgery.
  • The study revealed a statistically significant co-variation (p<0.05) between meningiomas grade II associated with several clinicopathological features (Simpson grade of clinical resection, necrosis, nuclear atypia, macronucleoli, transition to small cell, sheet-like growth, high cellularity), increased expression of several biomarkers of tumour proliferation (Cyclin A, Cyclin E, MIB-1 or MDM2), proteases (Cathepsin D) or cell-adhesion (CD44) and lower expression of progesterone receptors than meningiomas grade I.
  • The presence of Psammoma bodies or the location at convexity were protective prognostic factors for tumour recurrence while high cellularity and early age of onset (<57 year-old) were indicators of increased recurrence risk.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Chi-Square Distribution. Cohort Studies. Female. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Retrospective Studies. Sex Factors. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054806.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


46. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M: Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol; 2008 Jan;18(1):62-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity.
  • Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior.
  • Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas.
  • Deletion of the p16(INK4a)/p14(ARF) locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon.
  • Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Neurofibromin 2 / genetics
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Disease Progression. Drug Screening Assays, Antitumor / methods. Female. Gene Deletion. Genetic Predisposition to Disease / genetics. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Mice. Mice, Knockout. Mice, Mutant Strains. Mutation / genetics. Neoplasm Invasiveness / genetics. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / genetics. Neurofibromatosis 2 / physiopathology


47. Kondraganti S, Gondi CS, Gujrati M, McCutcheon I, Dinh DH, Rao JS, Olivero WC: Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol; 2006 Jul;29(1):25-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
  • It is secreted by all vascular cells and plays a role in tumor invasion and metastasis, presumably by plasmin-mediated matrix remodeling.
  • Previous studies have shown high expression of TFPI-2 by benign tumors and low or absent expression in highly malignant tumors.
  • Finally, TFPI-2 overexpression inhibited intracranial tumor formation in nude mice.
  • Our data substantiate our previous observation that TFPI-2 plays an important role in tumor progression and has potential in anti-cancer therapy.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Feb 20;317(1):311-4 [7872799.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] J Biochem. 1994 Nov;116(5):939-42 [7896752.001]
  • [Cites] Arch Biochem Biophys. 1995 May 10;319(1):55-62 [7539605.001]
  • [Cites] Eur J Biochem. 1996 Jan 15;235(1-2):310-6 [8631347.001]
  • [Cites] Cancer. 1996 May 1;77(9):1877-83 [8646688.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):267-8 [8661135.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Trends Biochem Sci. 1997 Aug;22(8):299-306 [9270303.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):40-6 [9445254.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2698-703 [9531578.001]
  • [Cites] Placenta. 1998 Mar-Apr;19(2-3):217-23 [9548189.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):749-56 [9610735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6 [9689032.001]
  • [Cites] Semin Thromb Hemost. 1998;24(3):207-10 [9701449.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4461-7 [9766679.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cell Death Differ. 1999 Jul;6(7):673-82 [10453078.001]
  • [Cites] Arch Biochem Biophys. 1999 Oct 1;370(1):112-8 [10496984.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):379-83 [7861006.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):127-31 [11115549.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12241-8 [11278667.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):239-44 [11315097.001]
  • [Cites] Int J Oncol. 2001 Sep;19(3):591-7 [11494041.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):325-33 [11606093.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6938-45 [11687973.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2184-91 [11929842.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7758-64 [2253219.001]
  • [Cites] J Biochem. 1990 Oct;108(4):537-43 [1963430.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5046-53 [1387587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • (PMID = 16773181.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glycoproteins; 0 / Laminin; 0 / Lipoproteins; 0 / Proteoglycans; 0 / bcl-2-Associated X Protein; 0 / lipoprotein-associated coagulation inhibitor; 0 / tissue-factor-pathway inhibitor 2; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS9141; NLM/ PMC1479607
  •  go-up   go-down


48. Chang SW, Gore PA, Nakaji P, Rekate HL: Juvenile intradural chordoma: case report. Neurosurgery; 2008 Feb;62(2):E525-6; discussion E527
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We report the youngest known case of a prepontine intradural chordoma.
  • These tumors are exceedingly rare.
  • Close follow-up is warranted because we postulate that this tumor exists in a biological continuum between benign notochordal hamartomatous remnants and typical invasive chordomas.
  • [MeSH-major] Chordoma / pathology. Chordoma / surgery. Dura Mater / pathology. Dura Mater / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382292.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Lichtenbaum R, de Souza AA, Jafar JJ: Intratumoral hydrogen peroxide injection during meningioma resection. Neurosurgery; 2006 Oct;59(4 Suppl 2):ONS470-3; discussion ONS473
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningiomas, although histologically benign, pose a particular challenge to the neurosurgeon because of their extensive and exuberant vascularity.
  • METHODS: Seventy-five patients underwent resection of a meningioma using the direct intratumoral H2O2 injection technique.
  • RESULTS: The use of this technique greatly facilitated the removal of these tumors.
  • [MeSH-major] Cerebral Hemorrhage / prevention & control. Hydrogen Peroxide / administration & dosage. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / surgery. Meningioma / drug therapy. Meningioma / surgery. Neurosurgical Procedures / adverse effects

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041519.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemostatics; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


50. Shah AB, Muzumdar GA, Chitale AR: Meningiomas: report of a hospital-based registry. Indian J Pathol Microbiol; 2005 Oct;48(4):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas: report of a hospital-based registry.
  • Of 1321 central nervous system tumours, meningiomas constituted 21% of the cases, being the second largest category of a single histologic type after astrocytomas.
  • 261 (98%) meningiomas were histologically benign and 5 were malignant meningiomas (1.9%).
  • Of note was the fact, that out of 261 patients with benign meningiomas, 11 succumbed in the immediate post-operative period and in 8 of these cases, the tumour was located at the base of the skull.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366096.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


51. Ahn ES, Chin LS, Gyure KA, Hudes RS, Ragheb J, DiPatri AJ Jr: Long-term control after resection and gamma knife surgery of an intracranial clear cell meningioma: case report. J Neurosurg; 2005 Apr;102(3 Suppl):303-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Authors have described its propensity to recur and metastasize despite its benign pathological characteristics.
  • The authors present the case of a 7-year-old girl with a large petroclival CCM who underwent a staged subtotal resection and subsequent gamma knife surgery (GKS).
  • Initially, the residual tumor decreased in size, but 6 years later, it had regrown (9 mm in size).
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881755.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9005-79-2 / Glycogen
  •  go-up   go-down


52. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are usually slow-growing benign tumors, for which complete removal can be difficult and recurrence is an issue.
  • Between January 1997 and December 2006, a total of 4885 intracranial tumors were diagnosed at Shohada Hospital, 378 (7.74%) of which were meningiomas.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • There was no relationship between the location of the tumor and the histopathological features.
  • Overall, the mitotic count was the most important marker for tumor grade.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


53. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • These tumors constitute a difficult clinical problem to handle.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • These patients harbored tumors within the radiosurgical target area.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Omeis I, Hillard VH, Braun A, Benzil DL, Murali R, Harter DH: Meningioangiomatosis associated with neurofibromatosis: report of 2 cases in a single family and review of the literature. Surg Neurol; 2006 Jun;65(6):595-603
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningioangiomatosis (MA) is a rare benign disorder.
  • Histopathologic examination showed the presence of a lesion consistent with MA.
  • MA should be considered in the differential diagnosis of cortical lesions, particularly in patients with NF2.
  • [MeSH-major] Cerebellar Neoplasms / complications. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningioma / complications. Meningioma / pathology. Neurofibromatosis 2 / complications
  • [MeSH-minor] Adolescent. Adult. Craniotomy / methods. Diagnosis, Differential. Female. Frontal Lobe. Humans. Magnetic Resonance Imaging. Neuroma, Acoustic / complications. Neuroma, Acoustic / surgery. Neurosurgical Procedures / methods. Parietal Lobe

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720184.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


56. Fukuoka S: [Stereotactic irradiation (Gamma knife) for benign brain tumors]. Nihon Rinsho; 2005 Sep;63 Suppl 9:412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic irradiation (Gamma knife) for benign brain tumors].
  • [MeSH-major] Cochlear Nerve. Cranial Nerve Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201556.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


57. Wang Y, Kang L, Xiao L: Infrequent bilateral orbital tumors and simulating lesions: the experience of a Chinese institute. Jpn J Ophthalmol; 2009 Nov;53(6):629-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrequent bilateral orbital tumors and simulating lesions: the experience of a Chinese institute.
  • RESULTS: The number and percentage of lesions in each general category were leukemia lesions in eight patients (19.5%), metastatic tumors in seven (17%), optic nerve and meningeal tumors in six (14.6%), secondary tumors in six (14.6%), peripheral nerve lesions in four (9.8%), inflammatory lesions in four (9.8%), and vasculogenic, histiocytic, and miscellaneous lesions, each in two patients (4.9%).
  • Of all cases, 51.2% were benign and 48.8% were malignant.
  • Of the 15 patients with either metastatic tumors or blood disorders, two (13.3%) had a history of primary neoplasm at presentation.
  • Through the combination of history, bilateral ocular manifestations, radiologic findings, and systemic examinations, the correct diagnosis can be made, which is valuable for early identification of both metastasis and blood disorders.
  • [MeSH-major] Orbital Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2002 Apr;109(4):753-6 [11927435.001]
  • [Cites] Surv Ophthalmol. 2004 May-Jun;49(3):281-99 [15110666.001]
  • [Cites] Am J Ophthalmol. 1967 Apr;63(4):723-6 [6022244.001]
  • [Cites] Arch Ophthalmol. 2005 Oct;123(10 ):1443-5 [16219741.001]
  • [Cites] Arch Ophthalmol. 1971 Jun;85(6):673-5 [5562786.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Dec;10(4):283-6 [7865452.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Sep;17 (5):346-54 [11642491.001]
  • [Cites] Acta Chir Plast. 2003;45(2):49-51 [12921259.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1963-9 [11733333.001]
  • [Cites] Ophthalmology. 1990 Nov;97(11):1519-31 [2255524.001]
  • [Cites] Arch Ophthalmol. 1990 Jan;108(1):80-3 [2105089.001]
  • [Cites] Br J Ophthalmol. 1992 Dec;76(12):755-7 [1486082.001]
  • [Cites] Acta Haematol. 1989;81(2):80-5 [2496555.001]
  • [Cites] Surv Ophthalmol. 1992 Nov-Dec;37(3):167-83 [1475751.001]
  • [Cites] Ophthalmology. 2003 Oct;110(10):2019-30 [14522782.001]
  • [Cites] Eye (Lond). 2008 Jul;22(7):980-1 [18049485.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):537-41 [11874758.001]
  • [Cites] Am J Ophthalmol. 1990 Aug 15;110(2):153-9 [2198811.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2007 Mar-Apr;23(2):87-93 [17413619.001]
  • [Cites] Ophthalmology. 1997 Apr;104(4):683-94 [9111264.001]
  • [Cites] Arch Ophthalmol. 1984 Nov;102(11):1606-11 [6497741.001]
  • (PMID = 20020243.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Gonzalez LF, Lekovic GP, Eschbacher J, Coons S, Spetzler RF: A true malignant schwannoma of the eighth cranial nerve: case report. Neurosurgery; 2007 Aug;61(2):E421-2; discussion E422
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The clinical presentation, pathology, treatment, and outcome of a 43-year-old woman with a malignant peripheral nerve sheath tumor arising from a benign schwannoma of the eighth cranial nerve are presented.
  • CLINICAL PRESENTATION: Initially, the tumor was debulked.
  • After finding malignant areas within the benign tumor, it was considered to be a malignant transformation of a previously benign tumor.
  • Postoperatively, the tumor bed was radiated for palliation.
  • [MeSH-major] Cranial Nerve Neoplasms / pathology. Neuroma, Acoustic / secondary. Vestibulocochlear Nerve / pathology
  • [MeSH-minor] Adult. Dura Mater / pathology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Meningeal Neoplasms / secondary

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762727.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Blomquist E, Bjelkengren G, Glimelius B: The potential of proton beam radiation therapy in intracranial and ocular tumours. Acta Oncol; 2005;44(8):862-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The estimations have been based on current statistics of tumour incidence, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours and normal tissues.
  • In intracranial benign and malignant tumours, it is estimated that between 130 and 180 patients each year are candidates for proton beam therapy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Eye Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Dosage
  • [MeSH-minor] Adenoma / radiotherapy. Chordoma / radiotherapy. Glioma / radiotherapy. Humans. Meningeal Neoplasms / radiotherapy. Pituitary Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Skull Neoplasms / radiotherapy. Sweden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16332593.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Protons
  • [Number-of-references] 93
  •  go-up   go-down


60. El Husseini M, Ianovici N, Dumitrescu GF, Mihăilă D, Plămădeală P, Haba D, Indrei A: [Posterior fossa meningiomas--topographic and anatomopathologic aspects]. Rev Med Chir Soc Med Nat Iasi; 2010 Jul-Sep;114(3):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Aspecte topografice şi anatomopatologice ale meningioamelor de fosă posterioară.
  • Meningiomas are the most frequent met intracranial tumors.
  • MATERIAL AND METHOD: Our study is focused on posterior fosa meningiomas, initially classified according to their origin based on IRM and surgical findings in order to identify correlations between demographic data, topographic tumor origin and anatomopathologic characteristics for each subgroup.
  • Benign meningiomas (1st degree) represented the unique subtype in tumors located in cerebellum convexity and foramen magnum.
  • [MeSH-major] Cranial Fossa, Posterior / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21243804.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


61. Bouvier C, Liprandi A, Colin C, Giorgi R, Quilichini B, Metellus P, Figarella-Branger D: Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol; 2005 Aug;124(2):252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas usually are benign intracranial tumors.
  • Pal expression correlated with cytogenetic data (P = .000033) and with recurrence (P = .0064); all tumors that recurred had abnormal Pal expression (13/13).
  • [MeSH-major] Alkaline Phosphatase / biosynthesis. Biomarkers, Tumor / analysis. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Neoplasm Recurrence, Local / enzymology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040297.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


62. Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, Yamamoto Y, Takano S, Matsumura A: New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol; 2008 Dec;18(12):2901-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases of 31 meningioma patients (27 benign and 4 nonbenign meningiomas) that underwent single-voxel 1H-MRS (PRESS sequence, TR/TE = 2,000 ms/68, 136, 272 ms) were retrospectively analyzed.
  • N-acetyl compounds(NACs) were observed in nine cases whose voxels were completely limited within the tumors, indicating that meningiomas might have endogenous NACs.
  • Lip not only represented micronecrosis in nonbenign meningiomas, but also reflected microcystic changes or fatty degeneration in benign meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Choline / analysis. Creatine / analysis. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / metabolism. Meningioma / diagnosis. Meningioma / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NMR Biomed. 2001 Aug;14(5):307-17 [11477651.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):85-9 [1650244.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):55-60 [11147898.001]
  • [Cites] Radiology. 1989 Aug;172(2):541-8 [2748837.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] Magn Reson Med. 2003 Apr;49(4):632-7 [12652533.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neuroradiology. 2007 Feb;49(2):121-7 [17086406.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • [Cites] Magn Reson Imaging. 1995;13(7):1019-29 [8583866.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3983-93 [11051247.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):769-75 [11395554.001]
  • [Cites] J Neurol. 1996 Oct;243(10):706-14 [8923303.001]
  • [Cites] Radiology. 1992 Jun;183(3):701-9 [1584924.001]
  • [Cites] Magn Reson Imaging. 1995;13(6):853-69 [8544657.001]
  • [Cites] Neuroradiology. 2003 Mar;45(3):129-36 [12684713.001]
  • [Cites] Neuroradiology. 2002 Jul;44(7):574-8 [12136358.001]
  • [Cites] J Comput Assist Tomogr. 1994 Sep-Oct;18(5):705-13 [8089316.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Magn Reson Imaging. 1993;11(1):107-18 [8423713.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] NMR Biomed. 1992 Jan-Feb;5(1):43-7 [1550709.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):663-72 [12915198.001]
  • [Cites] Nervenarzt. 2005 Apr;76(4):403-17 [15349736.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):606-13; discussion 613-4 [7808603.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):1-15 [8770242.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):99-108 [10982150.001]
  • [Cites] Clin Neuropathol. 1988 Jan-Feb;7(1):16-21 [3370860.001]
  • (PMID = 18641997.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


63. Das A, Tan WL, Smith DR: p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg; 2005 Jan;28(1):7-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While several studies have examined p53 both at the level of the gene and the protein in both benign and malignant meningiomas, its role remains controversial, particularly with regard to the discrepancy between p53 over-expression and gene mutation.
  • We examined 19 benign meningiomas, all of which were known to over-express p53, and eight malignant meningiomas, of which three were known to over-express p53, for mutations in the p53 gene using polymerase chain reaction amplification and direct sequencing of exons 4 to 9, inclusive.
  • Only one single mutation was detected in a benign meningioma, confirming that p53 over-expression in meningiomas is commonly found in the absence of gene mutations, and that despite the significantly higher incidence of meningiomas in some Asian populations, this is not associated with a significantly higher rate of p53 mutations.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691789.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


64. Friedman WA, Murad GJ, Bradshaw P, Amdur RJ, Mendenhall WM, Foote KD, Bova FJ: Linear accelerator surgery for meningiomas. J Neurosurg; 2005 Aug;103(2):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: In this paper the authors review the results of a single-center experience in the use of linear accelerator (LINAC) surgery for radiosurgical treatment of meningiomas.
  • The actuarial local control rate for benign tumors was 100% at both 1 and 2 years, and 96% at 5 years.
  • The actuarial local control rate for atypical tumors was 100% at 1 year, 92% at 2 years, and 77% at 5 years; and that for malignant tumors was 100% at both 1 and 2 years, and only 19% at 5 years.
  • CONCLUSIONS: Linear accelerator surgery produced high local control rates and very low rates of permanent morbidity in patients harboring benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Aug;103(2):203-5; discussion 205 [16175846.001]
  • (PMID = 16175847.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Bikmaz K, Mrak R, Al-Mefty O: Management of bone-invasive, hyperostotic sphenoid wing meningiomas. J Neurosurg; 2007 Nov;107(5):905-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The hyperostosis frequently associated with sphenoid wing meningiomas is actual invasion of bone by the tumor.
  • The intracranial portion of the tumor is usually thin with en plaque spread, and the tumor tends to invade the orbit through the superior orbital fissure.
  • Chromosome analysis was performed in all tumors resected since 2001 (seven cases).
  • These lesions are generally histologically benign.
  • [MeSH-major] Hyperostosis / pathology. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Invasiveness / pathology. Orbit / pathology
  • [MeSH-minor] Adult. Aged. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Recurrence, Local. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17977259.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


66. Ramina R, Neto MC, Fernandes YB, Aguiar PH, de Meneses MS, Torres LF: Meningiomas of the jugular foramen. Neurosurg Rev; 2006 Jan;29(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is controversy regarding the management of these tumors.
  • From a series of 107 patients that had been operated on for jugular foramen tumors between 1987 and 2005, ten had meningiomas.
  • A high incidence of malignant or aggressive tumors (six cases) was found.
  • Radical removal of benign jugular foramen meningiomas is possible.
  • The incidence of postoperative deficit of cranial nerves is higher than in other benign tumors of the jugular foramen.
  • A high incidence of aggressive (malignant) tumors was observed in this series.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1996 Jul;17(4):658-68 [8841718.001]
  • [Cites] Arq Neuropsiquiatr. 2004 Dec;62(4):997-1003 [15608958.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):373-7 [14736665.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Feb;106(2):128-36 [1738543.001]
  • [Cites] No Shinkei Geka. 1989 Jan;17 (1):87-92 [2651958.001]
  • [Cites] Otolaryngol Head Neck Surg (1979). 1979 Sep-Oct;87(5):578-83 [503520.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):903-9 [7472562.001]
  • [Cites] Laryngoscope. 2004 Jan;114(1):25-32 [14709990.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):279-84 [8545782.001]
  • [Cites] Laryngoscope. 1984 Jun;94(6):772-8 [6727514.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Am J Clin Pathol. 1989 Sep;92(3):266-72 [2476026.001]
  • [Cites] Neurosurg Focus. 2004 Aug 15;17(2):E5 [15329020.001]
  • [Cites] Otolaryngol Clin North Am. 1982 Nov;15(4):897-916 [6298686.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurgery. 2005 Apr;56(2 Suppl):337-43; discussion 337-43 [15794830.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):624-7 [1374854.001]
  • [Cites] Cancer. 1975 Oct;36(4):1363-73 [1175134.001]
  • [Cites] Surg Neurol. 1998 Dec;50(6):563-70 [9870817.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1014-24 [15200116.001]
  • [Cites] Surg Neurol. 1989 Apr;31(4):295-9 [2928924.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):59-68; discussion 59-68 [15987570.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):299-305 [3719522.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):143-7 [15696976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):501-4 [3042721.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Laryngorhinootologie. 1991 Jun;70(6):284-8 [1872929.001]
  • [Cites] Am J Surg. 1960 Sep;100:486-9 [13716296.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):12-20 [12134902.001]
  • [Cites] J Neurosurg Sci. 1997 Sep;41(3):283-92 [9444582.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Dec;44(4):211-7 [11830780.001]
  • (PMID = 16195869.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Azene EM, Gai QW, Tabar SP, Morrison AL, Meisenberg B: Metastasis of a histologically benign--appearing meningioma to the iliac bone. J Clin Oncol; 2008 Oct 1;26(28):4688-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a histologically benign--appearing meningioma to the iliac bone.
  • [MeSH-major] Bone Neoplasms / secondary. Ilium / pathology. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824717.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Asanuma K, Kasai Y, Takegami K, Ito H, Yoshikawa T, Uchida A: Spinal neurocutaneous melanosis without cutaneous nevi. Spine (Phila Pa 1976); 2008 Oct 1;33(21):E798-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To show a case and review the epidemiology, diagnosis and treatment of neurocutaneous melanosis without cutaneous nevi.
  • SUMMARY OF BACKGROUND DATA: Neurocutaneous melanosis is a rare congenital syndrome consisting of benign or malignant melanocytic tumors of the central nervous system and cutaneous nevi.
  • In general, patients are treated with palliative therapy, such as shunt placement to reduce intracranial pressure or tumor resection to reduce compression of the brain or spine.
  • Magnetic resonance imaging (MRI) of the spine revealed intradural tumor at the T5 level.
  • Computed tomography myelography showed intradural extramedullary tumor.
  • After the pigmented dura was opened, a pigmented tumor was resected.
  • RESULTS: Histologically, the pigmented tumor represented low grade.
  • The pigmented dura and bone comprised melanin-bearing cells without tumor cells.
  • Meningeal melanocytoma with leptomeningeal melanosis in the absence of cutaneous nevi was diagnosed.
  • CONCLUSION: This patient displayed spinal meningeal melanocytoma and leptomeningeal melanosis without cutaneous nevi.
  • The diagnosis in this case was speculated to represent a forme fruste of neurocutaneous melanosis.
  • [MeSH-major] Melanosis / radiography. Meningeal Neoplasms / radiography. Neurocutaneous Syndromes / radiography
  • [MeSH-minor] Adult. Humans. Male. Nevus, Intradermal / radiography. Nevus, Intradermal / surgery. Skin Neoplasms / radiography. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Neurocutaneous melanosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827686.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kondziolka D, Flickinger JC, Lunsford LD: The principles of skull base radiosurgery. Neurosurg Focus; 2008;24(5):E11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stereotactic radiosurgery is commonly used for selected patients with benign cranial base tumors.
  • The goal of radiosurgery is cessation of tumor growth and preservation of neurological function.
  • [MeSH-major] Cranial Irradiation / methods. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Brain Stem / physiopathology. Brain Stem / surgery. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Cranial Nerve Injuries / prevention & control. Decompression, Surgical. Diagnostic Imaging. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Patient Selection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


70. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • A case of a 54-year-old man diagnosed with an intracranial tumour located in the left frontal lobe is presented.
  • On pre-contrast CT scans, the tumour was hypodense and the contrast enhancement was marked in the pseudo membrane.
  • The tumour was partially removed.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Cranial Irradiation. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mitotic Index. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


71. Wang CL, Mei JH, Wang SS, Xu S, Xu LL, Xiong YF: [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):156-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the expression of HER2/neu, Ki-67 and TK1 protein in meningiomas in correlation with tumor grades and recurrence.
  • METHODS: Twenty cases of each of the following types of meningiomas were selected for the study, namely: the benign non-recurrent, recurrent benign, atypical and malignant, according to the World Health Organization (WHO) histological classification of nervous system, 2007.
  • The results of the biomarker assays were also used to study the correlationship with the tumor grades and tumor recurrency.
  • RESULTS: Immunohistochemistry showed that the positive rates of HER2 expression in non-recurrence benign group, recurrence benign group, atypical group and malignant group were 3 cases (15%), 6 cases (30%), 7 cases (35%), and 10 cases (50%), respectively (P < 0.05).
  • A higher tumor grade was correlated with a higher rate of HER2/neu expression.
  • Higher levels of LI of Ki-67 and TK1 were correlated with higher tumor grades and recurrence of the benign meningiomas (P < 0.05).
  • The rates of HER2/neu gene amplification were 0 in tumors with 1+ immunopositivity, 4/6 in tumor with 2+ immunopositivity and 3/4 in tumor with 3+ immunopositivity.
  • However, the rates of chromosome 17 aneuploidy had no significant difference among tumors with variable HER2/neu imumopositivity (P > 0.05).
  • CONCLUSIONS: High levels of HER2 and Ki-67 or TK1 expression correlate with the increase of tumor grades and tumor recurrence.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Aneuploidy. Chromosomes, Human, Pair 17. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Thymidine Kinase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450760.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


72. Castelli J, Thariat J, Benezery K, Courdi A, Chanalet S, Paquis P, Doyen J, Frenay M, Mammar H, Bondiau PY: [Spinals and paraspinals tumors treated by CyberKnife: feasibility and efficacy]. Cancer Radiother; 2010 Jan;14(1):5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spinals and paraspinals tumors treated by CyberKnife: feasibility and efficacy].
  • [Transliterated title] Tumeurs spinales et paraspinales traitées par irradiation stéréotaxique par CyberKnife((R)) au centre Antoine-Lacassagne de Nice.
  • PURPOSE: Stereotactic radiotherapy using the CyberKnife has become a key treatment in the multidisciplinary management of secondary tumours, as well as primary benign or malignant tumours located within or adjacent to vertebral bodies and the spinal cord.
  • The main advantages are better sparing of the spinal cord and the possibility of increasing the dose to the tumour target volume.
  • [MeSH-major] Radiosurgery. Spinal Neoplasms / mortality. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chordoma / mortality. Chordoma / surgery. Disease-Free Survival. Feasibility Studies. Female. Hemangioma / mortality. Hemangioma / surgery. Humans. Male. Meningeal Neoplasms / mortality. Meningeal Neoplasms / surgery. Meningioma / mortality. Meningioma / surgery. Middle Aged. Neoplasm Metastasis. Neurilemmoma / mortality. Neurilemmoma / surgery. Osteosarcoma / mortality. Osteosarcoma / surgery. Radiation Dosage. Radiometry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20005764.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


73. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L: Gamma Knife surgery for benign meningioma. J Neurosurg; 2007 Aug;107(2):325-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for benign meningioma.
  • OBJECT: Meningioma is the most frequent benign tumor treated with Gamma Knife surgery (GKS); however, the assessment of its efficacy and safety in slow-growing tumors is an ongoing process, requiring analysis of long-term results.
  • The median tumor volume was 4.4 cm3 (range 0.11-44.9 cm3).
  • The median tumor margin dose to the 50% isodose line was 12.55 Gy (range 6.5-24 Gy).
  • The volume of treated tumors decreased in 248 cases (69.7%), remained the same in 99 (27.8%), and increased in nine (2.5%).
  • The actuarial tumor control rate was 97.9% at 5 years post-GKS.
  • RESULTS: A significantly higher incidence of tumor volume increase was observed in men compared with women and in tumors treated with a margin dose lower than 12 Gy.
  • Significant risk factors for edema included an age greater than 60 years, no previous surgery, perilesional edema before radiosurgery, a tumor volume greater than 10 cm3, a tumor location in the anterior fossa, and a margin dose greater than 16 Gy.
  • A minimum margin dose of 12 to 16 Gy seems to represent the therapeutic window for benign meningiomas with a high tumor control rate in a mid-term follow-up period.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695387.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Pollock BE: Stereotactic radiosurgery of benign intracranial tumors. J Neurooncol; 2009 May;92(3):337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery of benign intracranial tumors.
  • Stereotactic radiosurgery is a frequently performed procedure for patients with benign intracranial tumors.
  • Benign tumors are good candidates for radiosurgery because they are generally non-invasive, are well visualized by magnetic resonance imaging, and their slow rate of proliferation makes conventional radiation dose fractionation unnecessary.
  • [MeSH-major] Adenoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2004 Mar;100(3):438-44 [15035279.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1254-61; discussion 1261-3 [15918941.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] J Neurosurg. 2007 May;106(5):833-8 [17542527.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1091-100 [12450031.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):500-4 [12243828.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:90-5 [11143270.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):255-66; discussion 255-66 [16883166.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12 [12843150.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1000-5 [12605979.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):699-705; discussion 699-705 [15792508.001]
  • [Cites] Neurosurgery. 2002 Nov;51(5):1153-9; discussion 1159-61 [12383360.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1983 Sep;46(9):797-803 [6352865.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1373-79; discussion 1379-80 [12445342.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):933-8 [9833818.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1002-8 [9609294.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1271-6; discussion 1276-8 [18824993.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):206-9 [16175847.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):215-24; discussion 224-9 [7708162.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):435-9 [11565865.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1287-9 [10720077.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1262-9; discussion 1269-70 [18824992.001]
  • [Cites] Neurosurgery. 2003 Mar;52(3):517-24; discussion 523-4 [12590675.001]
  • [Cites] J Neurosurg. 2006 Nov;105(5):657-61 [17121123.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:14-8 [11143231.001]
  • [Cites] Neurosurgery. 2008 Sep;63(3):435-40; discussion 440-2 [18812954.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):980-7 [17564168.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1):77-85; discussion 77-85 [16823303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):845-51 [17379451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31 [16029803.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Acta Chir Scand. 1951 Dec 13;102(4):316-9 [14914373.001]
  • [Cites] N Engl J Med. 1998 Nov 12;339(20):1426-33 [9811917.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):60-5; discussion 65-6 [17228253.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):876-83 [16776330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):275-80 [8892449.001]
  • [Cites] Neurosurgery. 2008 Sep;63(3):427-33; discussion 433-4 [18812953.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:62-7 [11143265.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Neurosurgery. 2005 May;56(5):927-35; discussion 927-35 [15854240.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):854-60 [17599761.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1325-9 [18029107.001]
  • [Cites] Otol Neurotol. 2002 Jul;23(4):534-41 [12170158.001]
  • (PMID = 19357960.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


75. Popovic MB, Diezi M, Kuchler H, Abouzeid H, Maeder P, Balmer A, Munier FL: Trilateral retinoblastoma with suprasellar tumor and associated pineal cyst. J Pediatr Hematol Oncol; 2007 Jan;29(1):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trilateral retinoblastoma with suprasellar tumor and associated pineal cyst.
  • Trilateral retinoblastoma (TRb) is a well-known syndrome associating hereditary retinoblastoma (Rb) with an intracranial neuroblastic tumor arising usually in the pineal region, rarely at the suprasellar or parasellar site.
  • It develops in most cases after diagnosis of Rb.
  • Pineal cysts have recently been reported as a benign variant of TRb.
  • We report the unusual presentation of a TRb in a 12-month-old boy with extensive bilateral Rb, a voluminous suprasellar tumor, pineal cyst, and leptomeningeal disease.
  • [MeSH-major] Central Nervous System Cysts / radiography. Eye Neoplasms / radiography. Meningeal Neoplasms / radiography. Pineal Gland / radiography. Retinoblastoma / radiography


76. Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K, Yoshida J: Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg; 2007 Aug;107(2):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to identify genes related to meningioma progression from the benign state to the atypical and anaplastic states by examining 1p LOH and the promoter methylation of RASSF1A and p73.
  • RESULTS: No 1p LOH was detected in the Grade I tumors, whereas it was detected in more than 80% of the Grade II and III tumors.
  • Methylation of the p73 promoter was observed in 81.8 and 71.4% of the Grade II and III tumors, respectively, but it was not observed in any of the Grade I tumors; methylation of the RASSF1A promoter was observed in 18.2, 63.6, and 42.9% of the Grade I, II, and III tumors, respectively.
  • Interestingly, 1p LOH and p73 promoter hypermethylation were detected in the malignantly transformed tumors but not in the lower-grade primary ones.
  • CONCLUSIONS: Based on the hypothesis that meningiomas cumulatively acquire genetic alterations and thus progress from the benign to the atypical and anaplastic states, genetic alterations in the methylation status of p73 or RASSF1A along with 1p LOH may result in the malignant transformation of a meningioma.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. DNA-Binding Proteins / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695396.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


77. Uzüm N, Ataoğlu GA: Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori; 2008 May-Jun;94(3):389-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: Meningiomas are classified following the WHO system of 2000 into three grades, benign (grade I), atypical (grade II), and anaplastic (grade III).
  • We investigated the relation between tumor grade and Ki-67 and bcl-2.
  • The relationship between tumor grade and morphological parameters like pattern, mitotic index, cellularity, pleomorphism, nucleoli, small cell population with high nucleus/cytoplasmic ratio, necrosis and brain invasion was examined.
  • RESULTS: A correlation was found between all morphologic parameters except for brain invasion.
  • Ki-67 and bcl-2 expression was correlated with tumor grade, and the higher the tumor grade, the higher the Ki-67 and bcl-2 expression.
  • In conclusion, tumor grade appeared to be the most important parameter for a prognosis of meningiomas.
  • CONCLUSIONS: Ki-67 and bcl-2 expression might participate in carcinogenesis and when used with the grading system could provide additional benefit in assessing the biological behavior of the tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningeal Neoplasms / pathology. Meningioma / chemistry. Meningioma / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705408.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


78. Kunert P, Matyja E, Janowski M, Marchel A: Rapid growth of small, asymptomatic meningioma following radiosurgery. Br J Neurosurg; 2009 Apr;23(2):206-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors present the case of a 62-year-old woman with rapid enlargement of a meningioma following radiosurgery (RS).
  • Previous slow growth of the tumor over a 3-year period and the radiological signs of benign meningioma had been confirmed by successive MR scans.
  • [MeSH-major] Meningeal Neoplasms. Meningioma. Postoperative Complications / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306181.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. von Randow AJ, Schindler S, Tews DS: Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas. Pathol Res Pract; 2006;202(5):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the majority of meningiomas, commonly benign tumors (WHO I), are amenable to surgical resection, a percentage of up to 3% will recur as higher-grade meningiomas with potential brain invasion.
  • There was a significant increase in positive tumor cells from WHO grade I to II and III for MMP-2 (p<0.001), but not for cathepsin D (p=0.099).
  • MMP-9 displayed an increased number of positive tumor cells from WHO grade I to II, but a decrease in WHO III meningiomas (p<0.002).
  • [MeSH-major] Cathepsin D / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Extracellular Matrix Proteins / metabolism. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563650.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; EC 3.4.23.5 / Cathepsin D; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


80. Tsutsumi S, Abe Y, Yasumoto Y, Shiono S, Ito M: Metastatic skull base tumor from thymic carcinoma mimicking Tolosa-Hunt syndrome. Neurol Med Chir (Tokyo); 2010;50(6):499-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic skull base tumor from thymic carcinoma mimicking Tolosa-Hunt syndrome.
  • Magnetic resonance imaging confirmed a broad-based, intensely enhanced extraaxial tumor of 4x4x4 cm diameter with dural tail sign.
  • Cerebral angiography demonstrated insignificant blood supply both from the internal carotid and middle meningeal arteries.
  • Nearly total tumor resection was achieved via orbitofrontotemporal craniotomy.
  • Intraoperative findings revealed the extraaxial tumor with broad attachment to the dura mater and invasion to the optic and oculomotor nerves.
  • Histological examination revealed hypercellular tumor with significant cell atypism, mitotic activity, and focal necrosis.
  • Systemic examination performed postoperatively revealed a thymic tumor without additional remote lesions.
  • The final diagnosis was metastatic brain tumor from thymic carcinoma.
  • Rapid progression of neurological impairment inconsistent with a benign extraaxial tumor needs prompt surgical intervention.
  • [MeSH-major] Carcinoma / secondary. Cranial Fossa, Anterior / pathology. Skull Base Neoplasms / secondary. Thymus Neoplasms / diagnosis. Tolosa-Hunt Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Tolosa Hunt syndrome.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587979.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Guevara P, Escobar-Arriaga E, Saavedra-Perez D, Martinez-Rumayor A, Flores-Estrada D, Rembao D, Calderon A, Sotelo J, Arrieta O: Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma. J Neurooncol; 2010 Jul;98(3):379-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are benign tumors, with low rate of recurrence after surgery.
  • We evaluated 42 patients with meningioma diagnosis (confirmed by histopathology) treated exclusively by surgery between January 1995 and December 1999, and compared the recurring and non-recurring groups after a ten-year follow-up period.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Recurrence, Local / diagnosis. Neovascularization, Pathologic / etiology. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropharmacol. 1984;7(4):363-7 [6509448.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):73-87 [18418552.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Folia Neuropathol. 2003;41(3):149-53 [14604296.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] J Neurosurg. 1989 Sep;71(3):347-51 [2769385.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1958 May;21(2):89-91 [13539648.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):333-40 [9689324.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):836-43 [3789250.001]
  • [Cites] Neurol Res. 2000 Mar;22(2):189-93 [10763508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Arch Neurol. 1987 Feb;44(2):209-15 [3545159.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Pathol Res Pract. 2008;204(9):655-62 [18565685.001]
  • [Cites] J Neurosurg. 1993 Mar;78(3):456-62 [8433149.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] J Neurooncol. 2009 May;92(3):317-35 [19357959.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):590-6 [1705973.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Mol Cell Biol. 1995 Jul;15(7):3463-9 [7791752.001]
  • [Cites] J Neurosurg. 1987 Mar;66(3):405-8 [3819835.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):184-91 [17483245.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 18;87(20):1499-501 [7563177.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):493-505 [10898356.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2612-24 [7739542.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] J Neurosurg. 1986 Jul;65(1):99-107 [3712034.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):679-85 [8033047.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Hum Pathol. 1996 Apr;27(4):350-4 [8617477.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1568-76 [16949911.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):743-9 [2213164.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:50-3 [8738495.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):297-300 [10499591.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):63-8 [17225937.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):68-75 [17200340.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):184-7 [8027799.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4800-9 [15256449.001]
  • [Cites] Neurology. 1975 Aug;25(8):705-12 [1171403.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1466-72 [2427189.001]
  • [Cites] J Cell Biol. 2004 Jun 21;165(6):789-800 [15197178.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4747-53 [9494601.001]
  • (PMID = 20013146.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


82. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


83. Ferrer M, Schulze A, Gonzalez S, Ferreiro V, Ciavarelli P, Otero J, Giliberto F, Basso A, Szijan I: Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases. Neurosci Lett; 2010 Aug 9;480(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of them are benign however, their location in the nervous system has harmful effects on important cranial and spinal structures.
  • These tumors are developed as the outcome of NF2 gene (22q12) inactivation.
  • The NF2 protein, merlin or schwannomin belongs to the Ezrin, Radixin, Moesin (ERM) family involved in the cytoskeletal network and has a tumor suppressor function.
  • Inactivating mutations occur as "de novo" (more frequently) or as inherited, and most of them are frameshift or nonsense.
  • [MeSH-minor] Adolescent. Adult. Aged. Argentina. Child. Ependymoma / genetics. Ependymoma / physiopathology. Female. Haplotypes. Humans. Male. Meningeal Neoplasms / genetics. Meningeal Neoplasms / physiopathology. Meningioma / genetics. Meningioma / physiopathology. Middle Aged. Molecular Diagnostic Techniques. Mutation. Pedigree. Young Adult


84. Gerber S, Ollivier L, Leclère J, Vanel D, Missenard G, Brisse H, de Pinieux G, Neuenschwander S: Imaging of sacral tumours. Skeletal Radiol; 2008 Apr;37(4):277-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All components of the sacrum (bone, cartilage, bone marrow, meninges, nerves, notochord remnants, etc.) can give rise to benign or malignant tumours.
  • Bone metastases and intraosseous sites of haematological malignancies, lymphoma and multiple myeloma are the most frequent aetiologies, while primary bone tumours and meningeal or nerve tumours are less common.
  • Some histological types have a predilection for the sacrum, especially chordoma and giant cell tumour.
  • [MeSH-major] Diagnostic Imaging. Sacrum / pathology. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Contrast Media. Diagnosis, Differential. Humans. Imaging, Three-Dimensional. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1989 Sep;(246):102-5 [2766597.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jan-Feb;16(1):164-6 [1729299.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Feb 15;21(4):522-6 [8658260.001]
  • [Cites] J Can Assoc Radiol. 1976 Dec;27(4):290-7 [993244.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):566-7 [3111222.001]
  • [Cites] AJNR Am J Neuroradiol. 1985 May-Jun;6(3):450-1 [3923808.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1691-7 [10584821.001]
  • [Cites] Radiology. 1993 May;187(2):445-8 [8475288.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):417-24 [10658718.001]
  • [Cites] Arch Orthop Trauma Surg. 1986;105(4):205-10 [3753174.001]
  • [Cites] Radiology. 1990 Jun;175(3):783-90 [2343130.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1198-202 [10506704.001]
  • [Cites] J Radiol. 2001 Apr;82(4):447-54 [11353899.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1699-706 [10584822.001]
  • [Cites] Radiographics. 2001 Jan-Feb;21(1):83-104 [11158646.001]
  • [Cites] Skeletal Radiol. 1993;22(5):362-6 [8372365.001]
  • [Cites] Radiology. 1990 Nov;177(2):467-72 [2217787.001]
  • [Cites] Skeletal Radiol. 1989;18(2):109-13 [2717949.001]
  • [Cites] AJR Am J Roentgenol. 1984 Apr;142(4):769-72 [6608238.001]
  • [Cites] Am J Clin Pathol. 1985 May;83(5):594-600 [3857854.001]
  • [Cites] Skeletal Radiol. 2002 Jul;31(7):413-8 [12107574.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):367-70 [9016209.001]
  • [Cites] J Comput Tomogr. 1987 Apr;11(2):151-5 [3581850.001]
  • [Cites] Int Orthop. 1998;22(1):19-26 [9549577.001]
  • [Cites] Clin Orthop Relat Res. 1977 Oct;(128):303-13 [598169.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Feb;15(2):293-7; discussion 298-9 [8192075.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Radiology. 1990 Jun;175(3):779-82 [2160676.001]
  • [Cites] Neuroradiology. 1998 Aug;40(8):524-6 [9763343.001]
  • [Cites] Neurosurg Focus. 2003 Aug 15;15(2):E2 [15350033.001]
  • [Cites] Radiographics. 1996 Sep;16(5):1131-58 [8888395.001]
  • [Cites] Spine (Phila Pa 1976). 1986 Jan-Feb;11(1):87-9 [3704795.001]
  • [Cites] J Pediatr Surg. 2000 Mar;35(3):515-8 [10726703.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1163-7 [7885566.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):955-60 [3872579.001]
  • [Cites] Clin Radiol. 1996 May;51(5):325-9 [8641093.001]
  • [Cites] J Surg Oncol. 2001 Apr;76(4):301-7 [11320524.001]
  • [Cites] Semin Nucl Med. 2006 Oct;36(4):286-94 [16950146.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):884-91 [2601818.001]
  • (PMID = 18034341.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 45
  •  go-up   go-down


85. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors


86. Adams H, Went P, Tolnay M, Sartorius G, Singer G: [Meningothelial meningioma in a mature cystic teratoma of the ovary]. Pathologe; 2007 Jul;28(4):278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Meningotheliomatöses Meningeom in einem reifen zystischen Teratom des Ovars.
  • Mature teratomas belong to the group of germ cell tumors of the ovary.
  • They account for 27-44% of all ovarian neoplasms and up to 58% of all benign tumors of the ovary.
  • In mature as well as in immature teratomas, secondary tumors originating from the three embryonic tissue components may be found.
  • These tumors can show benign or malignant behavior.
  • We report the case of a meningothelial meningioma, found within a mature teratoma of a 32 year old female.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology


87. Erkutlu I, Buyukhatipoglu H, Alptekin M, Berkyurek E, Tutar E, Gok A: Spinal drop metastases from a papillary meningioma: a case report and review of the literature: utility of CSF sampling. Med Oncol; 2009;26(2):242-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we report a rare case of a 29-year-old boy who presented with papillary meningioma originating from the posterior fossa meninges.
  • After a long, disease-free period, however, spinal drop metastases occurred 32 months after resection of the primary tumor.
  • The primary and metastatic lesions had a similar histological appearance, meaning that multiple spinal metastatic lesions occurred through CSF route even after a gross total resection of the tumor.
  • Tumor seeding during surgery is the evident reason for spinal metastasis, although we strictly adhered to the standard precautions for operations for malignant tumors such as obstruction of the cisterna magna with cotton paddies, and changing surgical gloves and instruments during the operation.
  • In this report, we briefly discuss an exceedingly rare variant of meningioma, the papillary variant, and suggest a new approach, a CSF sampling, in the management of both malignant and benign meningiomas.
  • CSF sampling allows for the early detection of metastasis and of tumor cells before metastasis has occurred, thus allowing treatment to begin as soon as possible.
  • Furthermore, we discussed that meningiomas are tumors that are not as benign as initially thought.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / secondary. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2002 Sep;97(3):683-6 [12296654.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Surg Neurol. 1994 Apr;41(4):299-305 [8165499.001]
  • [Cites] Cancer. 1975 Oct;36(4):1363-73 [1175134.001]
  • [Cites] Acta Neurol Scand. 2000 Sep;102(3):200-2 [10987382.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1975 Feb;38(2):136-42 [1151393.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):299-305 [3719522.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Clin Neuroophthalmol. 1989 Mar;9(1):55-9 [2522948.001]
  • (PMID = 18937081.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


88. Crabtree KL, Arnold PM: Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously. Pediatr Neurosurg; 2010;46(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously.
  • Pilocytic astrocytoma (PA) is a slow-growing, well-circumscribed grade I glioma generally considered benign, with a low recurrence rate and an excellent prognosis following complete surgical resection.
  • To our knowledge, this is the longest time reported from initial tumor resection of leptomeningeal dissemination to the distal spinal cord.
  • PA patients with subtotal resection may benefit from continued follow-up for up to 20 years after the initial diagnosis and resection.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasm Seeding. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516744.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


89. Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol; 2010 Dec;12(12):1278-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal.
  • Understanding the potential behavior of these tumors in individual patients is critical for rational therapeutic decision-making.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 6 / genetics. Histones / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):708-15 [12861068.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14 [14506147.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):939-43 [15375526.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1199-212 [16377562.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9113-26 [18258596.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] Mol Cancer. 2008;7:93 [19099607.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Biofactors. 2009 Mar-Apr;35(2):200-8 [19449449.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):409-20 [18637901.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1395-407 [19885562.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2584-93 [19847810.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • (PMID = 20685720.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones
  • [Other-IDs] NLM/ PMC3018937
  •  go-up   go-down


90. Bodi I, Hortobágyi T, Buk S: A 72-year-old woman with right frontal extra-axial mass. Brain Pathol; 2008 Apr;18(2):279-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology showed a benign meningioma with multifocal accumulation of numerous large cells with abundant eosinophilic cytoplasm, filled with lamellar inclusions and bipyramidal crystals.
  • Plasma cell inclusions have been reported occasionally in reactive inflammatory lesions but more frequently in plasma cell tumors and lymphoplasmacytic lymphoma, maybe associated with crystal-storing histiocytosis.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363938.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A: Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol; 2009 Jul;19(3):409-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.
  • Cytogenetic analysis is a powerful tool for predicting recurrence in meningiomas, even among histologically benign/grade I tumors.
  • Despite this, no study has been reported in which the impact of tumor cytogenetics on the gene expression profiles (GEP) has been analyzed in meningiomas.
  • Here, we analyzed the GEP of 47 tumors and correlated them with the most clinical relevant cytogenetic subgroups of meningiomas, as confirmed through the analysis of 172 patients.
  • Additionally three normal meningeal samples were also studied.
  • Overall, our results show a clear association between the clinically relevant cytogenetic subgroups of meningiomas including diploid tumors (n = 18), isolated -22/22q- (n = 12), del(1p36) alone (n = 4) and complex karyotypes associated with del(1p36) and/or -14q (n = 13) and their GEP.
  • Accordingly, based on the expression of 85 genes (40 of which were coded in the altered chromosomes used for patient stratification) the cytogenetic class of the tumor could be predicted with an error of <1%, a clear association being found between the GEP and patient outcome (P = 0.03) but not tumor histopathology.
  • [MeSH-major] Cytogenetic Analysis. Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637901.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


92. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol; 2010 Nov;100(2):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
  • Prediction of recurrence remains a challenge in histopathological benign/grade I tumors.
  • In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas.
  • Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II).
  • We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN.
  • In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time.
  • Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Osteopontin / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2004 Feb;61(2):149-55; discussion 155-6 [14751627.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Neuro Oncol. 2010 Jan;12(1):58-70 [20150368.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):375-83 [10470810.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):135-46 [11005509.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29 [12013531.001]
  • [Cites] J Cell Biochem. 2000 Jun 6;78(3):465-75 [10861844.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):212-26 [18292776.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):383-8 [19330289.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):199-207 [19801161.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):63-8 [17225937.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Curr Mol Med. 2006 Dec;6(8):819-30 [17168734.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):203-7 [19048398.001]
  • (PMID = 20428925.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


93. Mineo JF, P-Ruchoux MM, Pasquier D, Rigolle H, Assaker R: [Primitive malignant melanoma arising in a spinal nerve root. A case report]. Neurochirurgie; 2006 Jun;52(2-3 Pt 1):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The T1-weighted MRI images showed a tumor hyperintensity, the T2-weighted images showed tumor isointensity and mild contrast enhancement.
  • Due to the scalloping of L3/L4 foramen with root enlargement and slow evolution (more than one year between the first symptom and surgery without clinical worsening), the initial preoperative diagnosis was L3 schwannoma.
  • The tumor was composed of irregular melanocytoid cells with high proliferation index (20%).
  • So, the final diagnosis was intradural primitive malignant melanoma.
  • Radiotherapy was performed on the site of the tumor.
  • The most common tumor with root enlargement and bony scalloping is the benign schwannoma.
  • Despite the above described radiological features, MRI characteristics (hyperintensity when images are T1-weighted) suggest a melanocytic tumor, a tumor with a high adipose component or an intratumoral bleeding.
  • Specific MRI sequences can eliminate adipose tissue tumor, but diagnosis between melanin and methemoglobin is still difficult.
  • According to the index of proliferation, a primitive central melanocytic lesion can be a meningeal melanocytoma (considered as benign) or a primitive malignant melanoma.
  • These tumors show identical protein expressions in immunohistochemistry, and their prognosis is very variable (some long-term remissions are reported for malignant melanomas and fast disseminations are described for meningeal melanocytomas treated by sub-total surgery).
  • The histological features of malignant lesion with benign clinical features lead to interrogation upon the actual pathologic classification.
  • [MeSH-major] Melanoma / pathology. Spinal Neoplasms / pathology. Spinal Nerve Roots / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm. Cell Proliferation. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Melanins / metabolism. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. Neurologic Examination. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840974.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanins; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


94. Poliani PL, Sperli D, Valentini S, Armentano A, Bercich L, Bonetti MF, Corriero G, Brisigotti M, Quattrone A, Lanza PL: Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case. Neuropathology; 2009 Oct;29(5):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case.
  • Cerebral and spinal location of glioneuronal tumors have been recently described as a novel type of primary CNS neoplasia.
  • A distinctive rare form of glioneuronal tumors with neuropil-like islands (GTNI) have been reported to occur in the adult cerebrum, whereas spinal GTNI localization is extremely rare.
  • In the present report we describe a case of a 15-month-old child with a spinal GTNI of the cervical region and meningeal dissemination.
  • Histologically the tumor was composed of round, small neurocytic-like cells arranged around eosinophilic neuropil cores and embedded in a diffuse fibrillar glial component forming prominent "rosetted" neuropil islands displaying strong immunoreactivity for neuronal markers.
  • Nevertheless, due to their exceptional rarity, the natural history of these lesions is not yet fully understood, but spinal GTNI seems to have an unfavorable clinical course despite their benign histopathological features, which must be taken into account for appropriate treatment and follow-up of the patient.
  • [MeSH-major] Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Neoplasms, Nerve Tissue / pathology. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077041.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


95. McCall T, Binning M, Blumenthal DT, Jensen RL: Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature. Surg Neurol; 2006 Jul;66(1):62-7; discussion 67-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Choroid plexus papillomas are typically considered benign lesions, but histology is not always predictive of their behavior.
  • These tumors can metastasize anywhere along the neuraxis and may be intraventricular, subarachnoid, or intraparenchymal.
  • Patient 2 also had a primary fourth ventricular tumor but with subsequent suprasellar and spinal drop metastases.
  • [MeSH-major] Choroid Plexus / pathology. Choroid Plexus / surgery. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / therapy

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793445.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


96. Smith AB, Rushing EJ, Smirniotopoulos JG: Pigmented lesions of the central nervous system: radiologic-pathologic correlation. Radiographics; 2009 Sep-Oct;29(5):1503-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pigmented lesions of the central nervous system (CNS) are a diverse group of entities that run the gamut from benign to malignant.
  • Pigmented lesions include primary melanocytic lesions of the CNS and metastatic melanoma, as well as other CNS neoplasms that may undergo melanization, including schwannoma, medulloblastoma, and some gliomas.
  • Primary melanocytic lesions of the CNS arise from melanocytes located within the leptomeninges, and this group includes diffuse melanocytosis and meningeal melanomatosis (seen in neurocutaneous melanosis), melanocytoma, and malignant melanoma.
  • Absence of a known primary malignant melanoma helps in the differential diagnosis, but an occult primary lesion outside the CNS must be sought and excluded.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Diagnostic Imaging / methods. Pigmentation Disorders / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19755608.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


97. Rahman M, Murad GJ, Bova F, Friedman WA, Mocco J: Stereotactic radiosurgery and the linear accelerator: accelerating electrons in neurosurgery. Neurosurg Focus; 2009 Sep;27(3):E13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiosurgery is truly minimally invasive, delivering therapeutic energy to an accurately defined target without an incision, and has been used to treat a wide variety of pathological conditions, including benign and malignant brain tumors, vascular lesions such as arteriovenous malformations, and pain syndromes such as trigeminal neuralgia.
  • [MeSH-minor] Brain Neoplasms / surgery. History, 20th Century. Humans. Meningeal Neoplasms / surgery. Minimally Invasive Surgical Procedures / methods. Monitoring, Intraoperative. Neurosurgical Procedures / history. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Radiotherapy / methods. Treatment Outcome. Trigeminal Neuralgia / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722815.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


98. De Stefano A, Dispenza F, Di Trapani G, Kulamarva G: Meningioma of the cerebellopontine angle mimicking benign paroxysmal positional vertigo. J Otolaryngol Head Neck Surg; 2008 Apr;37(2):E46-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma of the cerebellopontine angle mimicking benign paroxysmal positional vertigo.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Vertigo / etiology
  • [MeSH-minor] Cerebellopontine Angle. Contrast Media / administration & dosage. Diagnosis, Differential. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Benign Paroxysmal Positional Vertigo.
  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19137657.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


99. Pamir MN, Kilic T, Ozek MM, Ozduman K, Türe U: Non-meningeal tumours of the cavernous sinus: a surgical analysis. J Clin Neurosci; 2006 Jul;13(6):626-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-meningeal tumours of the cavernous sinus: a surgical analysis.
  • The purpose of this study was first to analyse, define and summarise the individual characteristics of different non-meningeal tumours of the cavernous sinus and, secondly, to stress that their surgery can be accomplished with acceptable morbidity and rewarding results when those characteristics are considered.
  • A retrospective analysis of 42 cases of benign non-meningeal tumours of the cavernous sinus operated on at Marmara University between April 1992 and April 2003 is presented.
  • Non-meningeal tumours of the cavernous sinus can be surgically resected with acceptable morbidity and mortality.
  • Individual tumour characteristics are presented in the text.
  • [MeSH-major] Brain Neoplasms / surgery. Cavernous Sinus / surgery. Neoplasms, Vascular Tissue / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Cranial Nerve Neoplasms. Female. Follow-Up Studies. Hemangioma, Cavernous, Central Nervous System. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurilemmoma / surgery. Pituitary Neoplasms / surgery. Retrospective Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860718.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


100. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol; 2010 Jan;96(2):211-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):45-51 [8583244.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36 [16319713.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1047-51 [17353924.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • (PMID = 19562255.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / U01 CA062421-06; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA062421-06; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS511532; NLM/ PMC3786190
  •  go-up   go-down






Advertisement